New fund targets companies battered by market doubts
Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund.
Source: afr.com
Karst Peak News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Karst Peak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Karst Peak Today - Breaking & Trending Today
CurveBeam AI: Brian Flannery-backed medical imaging company CurveBeam AI kicks off $15m pre-IPO led by Bell Potter and Lodge Corporate
Brian Flannery-backed bone fragility imaging tech company CurveBeam AI is tapping investors for $15 million ahead of a 2023 float.
Source: afr.com
Local AI start-up StraxCorp merges with US imaging tech player CurveBeam ahead of ASX IPO
Brian Flannery-backed bone fragility imaging tech company StraxCorp is merging with US CT imaging disrupter CurveBeam and kick-starting a pre-IPO raise.
Source: afr.com
Why Neuren Pharmaceuticals is Karst Peak and Milford Asset Management's top biotech pick
Neuren Pharmaceuticals’ share price has almost doubled in six months, but investors think it’s still undervalued as it approaches its first FDA approval.
Source: afr.com
Pharmaxis Ltd has multiple potential value inflection points with two drugs advancing in clinical trials
Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are due to report meaningful efficacy and safety endpoints in patients by the end of 2022. The company has a platform technology that has delivered a pipeline of first in class or best in class clinical drugs for inflammatory and fibrotic diseases. The first of these drugs already has an IND approval from the FDA and is currently being trialled in myelofibrosis patients. Its lead asset PXS-5505 – with disease-modifying potential in myelofibrosi...
Source: proactiveinvestors.com